Australia markets close in 3 hours 5 minutes
  • ALL ORDS

    7,310.90
    -17.10 (-0.23%)
     
  • ASX 200

    7,044.30
    -21.30 (-0.30%)
     
  • AUD/USD

    0.7795
    +0.0037 (+0.48%)
     
  • OIL

    63.80
    +0.42 (+0.66%)
     
  • GOLD

    1,768.30
    -2.30 (-0.13%)
     
  • BTC-AUD

    69,941.97
    -3,417.78 (-4.66%)
     
  • CMC Crypto 200

    1,242.70
    -56.25 (-4.33%)
     
  • AUD/EUR

    0.6462
    +0.0020 (+0.31%)
     
  • AUD/NZD

    1.0815
    +0.0017 (+0.15%)
     
  • NZX 50

    12,591.10
    -176.73 (-1.38%)
     
  • NASDAQ

    13,907.67
    -134.24 (-0.96%)
     
  • FTSE

    7,000.08
    -19.45 (-0.28%)
     
  • Dow Jones

    34,077.63
    -123.04 (-0.36%)
     
  • DAX

    15,368.39
    -91.36 (-0.59%)
     
  • Hang Seng

    29,054.59
    -51.56 (-0.18%)
     
  • NIKKEI 225

    29,150.71
    -534.66 (-1.80%)
     

Merck says study shows COVID-19 drug causes quick reduction in virus

·1-min read

March 6 (Reuters) - U.S. drugmaker Merck & Co Inc said on Saturday the experimental antiviral drug molnupiravir it is developing with Ridgeback Bio showed a quicker reduction in infectious virus in its phase 2a study among participants with early COVID-19.

"The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising," said William Fischer, Associate Professor of Medicine at the University of North Carolina School of Medicine, in a statement from the companies.

The antiviral is being currently tested in a Phase 2/3 trial that is set to be completed in May.

Merck decided to focus on therapeutics after its two COVID-19 vaccines failed to generate desired immune responses, prompting it to abandon the program in January.

(Reporting by Ann Maria Shibu in Bengaluru; Editing by Christian Schmollinger)